Central compartment revision surgery for persistent or recurrent thyroid carcinoma: analysis of survival and complication rate.
Adult
Aged
Aged, 80 and over
Carcinoma, Medullary
/ mortality
Carcinoma, Papillary
/ mortality
Cohort Studies
Female
Humans
Hypocalcemia
/ etiology
Male
Middle Aged
Neck Dissection
Neoplasm Recurrence, Local
/ mortality
Postoperative Complications
Prognosis
Reoperation
Retrospective Studies
Thyroid Neoplasms
/ mortality
Thyroidectomy
Vocal Cord Paralysis
/ etiology
Young Adult
Central compartment
Complications
Hypocalcemia
Neck dissection
Nodal metastases
Thyroid cancer
Vocal fold palsy
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
08
10
2018
accepted:
06
12
2018
pubmed:
12
12
2018
medline:
11
4
2019
entrez:
12
12
2018
Statut:
ppublish
Résumé
Locoregional recurrence of thyroid carcinoma is relatively common and reported rate are between 5 and 20%. Cervical nodes are usually involved, especially at the central compartment. The management of recurrent thyroid carcinoma at central compartment still remains challenging because of higher incidence of complication rate. The aim of the study is to evaluate the survival and complications rate after revision surgery. Retrospective cohort study on a group of patients that underwent revision surgery for persistent or recurrent thyroid carcinoma from January 1, 2003 to December 31, 2017. Survival outcomes were calculated using Kaplan-Meier method. Significant variables on univariate analysis were subjected to a Cox proportional hazards regression multivariate model. Fifty-two patients involved, 22 male (40%) and 30 female (60%). Mean age was 54 years old (range 24-85). Mean follow-up was 79 months, median follow-up was 85 months, with a range between 8 and 153 months. The 5-year overall survival was 90.8% while at 10 years it was 69.8%. The 5-year disease-specific survival was 93.5%, while at 10 years it dropped to 77.9%. The rate of recurrent laryngeal nerve paralysis and persistent hypocalcemia in our series were 1.3% and 5.9%, respectively. No evidence of thoracic duct, esophageal or laryngeal and tracheal injury was found in this case series. Regarding prognostic factors, univariate and multivariate analysis highlighted as statistically significant: the aggressive histological variants, the presence extranodal extension or soft-tissue metastasis. The surgical option remains the gold standard in locoregional recurrences of thyroid carcinoma and should be performed by experienced surgeons to reduce postoperative complications.
Identifiants
pubmed: 30535975
doi: 10.1007/s00405-018-5239-2
pii: 10.1007/s00405-018-5239-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
551-557Références
Head Neck. 2009 Sep;31(9):1152-63
pubmed: 19360746
Br J Surg. 2009 Mar;96(3):240-6
pubmed: 19177420
Laryngoscope. 2011 May;121(5):1009-17
pubmed: 21520117
Head Neck. 2007 Dec;29(12):1069-74
pubmed: 17563908
J Craniofac Surg. 2014 Sep;25(5):1797-800
pubmed: 25098577
J Nucl Med. 1996 Apr;37(4):598-605
pubmed: 8691248
J Voice. 2010 Jan;24(1):119-25
pubmed: 19185462
Thyroid. 2018 Jul;28(7):830-841
pubmed: 29848235
Surgery. 2009 May;145(5):514-8
pubmed: 19375610
Ann Surg Oncol. 2011 May;18(5):1312-8
pubmed: 21140230
Arch Otolaryngol Head Neck Surg. 2004 Oct;130(10):1214-6
pubmed: 15492172
Thyroid. 2011 Dec;21(12):1309-16
pubmed: 22136266
Arch Surg. 2010 Mar;145(3):272-5
pubmed: 20231628
Oral Oncol. 2013 Jul;49(7):689-94
pubmed: 23623403
Laryngoscope. 2011 Jan;121 Suppl 1:S1-16
pubmed: 21181860
Arch Otolaryngol Head Neck Surg. 2012 Jan;138(1):33-7
pubmed: 22249626
J Clin Endocrinol Metab. 2013 May;98(5):1819-25
pubmed: 23493434
Ann Surg Oncol. 2012 Sep;19(9):2951-7
pubmed: 22526913
JAMA Otolaryngol Head Neck Surg. 2018 Feb 1;144(2):108-114
pubmed: 29192312
JAMA Otolaryngol Head Neck Surg. 2017 Apr 1;143(4):376-381
pubmed: 28097314
J Clin Endocrinol Metab. 2012 May;97(5):1526-35
pubmed: 22344193
Laryngoscope. 2009 Oct;119(10):1947-50
pubmed: 19650129
J Natl Compr Canc Netw. 2005 May;3(3):404-57
pubmed: 16002006
BMC Cancer. 2014 Jun 05;14:405
pubmed: 24906384
Endocr Pract. 2012 Jul-Aug;18(4):600-3
pubmed: 22849875
Laryngoscope. 2008 May;118(5):768-75
pubmed: 18197134
World J Surg. 2013 Dec;37(12):2853-9
pubmed: 24045964
J Voice. 2017 Jul;31(4):517.e1-517.e7
pubmed: 28131460